Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.

NCT02583464 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Acquired Immunodeficiency Syndrome

Interventions

DRUG: Tenofovir disoproxil fumarate and emtricitabine

Sponsor

Laboratorio Elea Phoenix S.A.